Harvard Bioscience
HBIO
81 hedge funds and large institutions have $72.1M invested in Harvard Bioscience in 2016 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 29 increasing their positions, 26 reducing their positions, and 5 closing their positions.
12% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 26
0% more funds holding
Funds holding: 81 → 81 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
12% less capital invested
Capital invested by funds: $82.2M → $72.1M (-$10.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$638K |
| 2 |
PCMI
Paradigm Capital Management Inc
Albany,
New York
|
+$321K |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$313K |
| 4 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$154K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$146K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIC
Woodmont Investment Counsel
Nashville,
Tennessee
|
-$357K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$276K |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$202K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$122K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$113K |
HBIO Hedge Fund Activity: Q1 2016 in Review
81 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q1 2016, worth a combined $72.1M — down 12% from $82.2M a quarter earlier.
Fund positioning in HBIO was balanced in Q1 2016: 5 funds opened new positions, 5 closed out, 29 added to existing stakes and 26 trimmed.
The largest buyer was Royce & Associates, adding an estimated $638K. The largest seller was Woodmont Investment Counsel, cutting an estimated $357K.
- 81 institutional investors held Harvard Bioscience (HBIO) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $72.1M of Harvard Bioscience stock for Q1 2016, down 12% quarter-over-quarter.
- 5 funds opened new Harvard Bioscience positions in Q1 2016 and 5 closed out, a net change of 0 holders.
- The largest Harvard Bioscience buyer in Q1 2016 was Royce & Associates, an estimated $638K added.
- The largest Harvard Bioscience seller in Q1 2016 was Woodmont Investment Counsel, an estimated $357K sold.
Based on aggregated 13F filings for Q1 2016.